A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subjects with primary Sjogren's syndrome

Trial Profile

A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in subjects with primary Sjogren's syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Belimumab (Primary) ; Rituximab
  • Indications Sjogren's syndrome
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Nov 2017 Planned primary completion date changed from 21 May 2019 to 29 Jan 2019.
    • 10 Aug 2017 Planned End Date changed from 22 Jan 2020 to 28 Jan 2020.
    • 10 Aug 2017 Planned primary completion date changed from 15 May 2019 to 21 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top